EUVIMEDEUVIMED entdecken
Pragmatische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial

Niklas Dyrby Johansen, Daniel Modin, Kristoffer Grundtvig Skaarup, Joshua Nealon, Sandrine Samson, Marine Dufournet, Matthew M Loiacono, Rebecca C Harris, Carsten Schade Larsen, Anne Marie Reimer Jensen, Nino Emanuel Landler, Brian L Claggett und 10 weitere

Clinical Microbiology and Infection · 2024

DOI: 10.1016/j.cmi.2024.01.017 ↗

Kurz gefasst

Pragmatische Studie in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Niklas Dyrby Johansen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Heal…. Hauptthemen laut MEDLINE: Hospitalization, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Sanofi Pasteur SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate the relative effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) against recurrent hospitalizations and its potential variation in relation to influenza circulation. METHODS: We did a post-hoc analysis of a pragmatic, open-label, randomized trial of QIV-HD versus QIV-SD performed during the 2021-2022 influenza season among adults aged 65-79 years. Participants were enrolled in October 2021-November, 2021 and followed for outcomes from 14 days postvaccination until 31 May, 2022. We investigated the following outcomes: Hospitalizations for pneumonia or influenza, respiratory hospitalizations, cardio-respiratory hospitalizations, cardiovascular hospitalizations, all-cause hospitalizations, and all-cause death. Outcomes were analysed as recurrent events. Cumulative numbers of events were assessed weekly. Cumulative relative effectiveness estimates were calculated and descriptively compared with influenza circulation. The trial is registered at Clinicaltrials.gov: NCT05048589. RESULTS: Among 12,477 randomly assigned participants, receiving QIV-HD was associated with lower incidence rates of hospitalizations for pneumonia or influenza (10 vs. 33 events, incidence rate ratio [IRR] 0.30 [95% CI, 0.14-0.64]; p 0.002) and all-cause hospitalizations (647 vs. 742 events, IRR 0.87 [95% CI, 0.76-0.99]; p 0.032) compared with QIV-SD. Trends favouring QIV-HD were consistently observed over time including in the period before active influenza transmission; i.e. while the first week with a ≥10% influenza test positivity rate was calendar week 10, 2022, the first statistically significant reduction in hospitalizations for pneumonia or influenza was already observed by calendar week 3, 2022 (5 vs. 15 events, IRR 0.33 [95% CI, 0.11-0.94]; p 0.037). DISCUSSION: In a post-hoc analysis, QIV-HD was associated with lower incidence rates of hospitalizations for pneumonia or influenza and all-cause hospitalizations compared with QIV-SD, with trends evident independent of influenza circulation levels. Our exploratory results correspond to a number needed to treat of 65 (95% CI 35-840) persons vaccinated with QIV-HD compared with QIV-SD to prevent one additional all-cause hospitalization per season. Further research is needed to confirm these hypothesis-generating findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationInfluenza VaccinesInfluenza, HumanAgedFemaleHumansMalePneumoniaVaccine EfficacyTreatment OutcomeDose-Response Relationship, ImmunologicRecurrence

Stichwörter der Autor:innen

InfluenzaPneumoniaPragmaticRandomized controlled trialRegistryVaccine

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, Center for Translational Cardiology and Pragm…
  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China.
  • Sanofi, Lyon, France.
  • Sanofi, Swiftwater, PA, USA.
  • Sanofi, Singapore.
  • Department of Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Förderung

  • Sanofi
  • Sanofi Pasteur SA

Zitieren

APA

Johansen, N. D., Modin, D., Skaarup, K. G., Nealon, J., Samson, S., Dufournet, M., Loiacono, M. M., Harris, R. C., Larsen, C. S., Jensen, A. M. R., Landler, N. E., Claggett, B. L., Solomon, S. D., Landray, M. J., Gislason, G. H., Køber, L., Jensen, J. U. S., Sivapalan, P., Vestergaard, L. S., …, & Biering-Sørensen, T. (2024). Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.01.017

Vancouver

Johansen ND, Modin D, Skaarup KG, Nealon J, Samson S, Dufournet M, et al. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2024.01.017

BibTeX
@article{Johansen2024,
  author = {Johansen, Niklas Dyrby and Modin, Daniel and Skaarup, Kristoffer Grundtvig and Nealon, Joshua and Samson, Sandrine and Dufournet, Marine and Loiacono, Matthew M and Harris, Rebecca C and Larsen, Carsten Schade and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Claggett, Brian L and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Jensen, Jens Ulrik Stæhr and Sivapalan, Pradeesh and Vestergaard, Lasse Skafte and Valentiner-Branth, Palle and Krause, Tyra Grove and Biering-Sørensen, Tor},
  title = {Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial},
  journal = {Clinical Microbiology and Infection},
  year = {2024},
  doi = {10.1016/j.cmi.2024.01.017}
}
Kostenlos starten →